SAN FRANCISO, CA / ACCESSWIRE / January 26, 2018 / Seattle based Atossa Genetics Inc. (NASDAQ: ATOS) is a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. They believe their innovative therapies and delivery methods can transform breast cancer treatment.
Early Friday morning shares of Atossa Genetics surged almost 40% and are currently up ~25% with 13,560,000 having traded. The average trading volume is 2,180,000 shares per day.
This week Atossa Genetics received additional support and sponsorship from both Vista Partners LLC and Maxim Group as both firms published favorable reports. Maxim Group initiated coverage with a "buy" & set a 12-month price target of $2/share.
Vista Partners Managing Director John F. Heerdink, Jr. stated, "During the fourth-quarter 2017, Atossa Genetics announced that they have started a new program to deliver CAR-T cells into the ducts of the breast for the potential targeted treatment of breast cancer. CAR-T has been the subject of much attention recently. In October 2017, pioneer CAR-T company Kite Pharma was acquired for ~$12B billion by Gilead (GILD). This week Celgene (CELG) announced that they are acquiring Juno Therapeutics, Inc. (JUNO) for approximately $9 billion."
DOWNLOAD the Vista Partners FREE Report at http://www.vistapglobal.com/vp-coverage/atossa-genetics-inc-atos/.
Vista Partners offers a wealth of mixed-media resources on the Dow 30 & Select Emerging Growth Companies. Visit www.vistapglobal.com/signup to stay informed & competitive with FREE email updates.
About VISTA PARTNERS
Founded in 2005, Vista Partners LLC ('Vista') is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista's proprietary equity and market research to help you stay informed and stay competitive. Vista's mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
We encourage readers to view a complete list of disclaimers and disclosures on the Vista Partners website at VistaPGlobal.com/disclaimer.
Please follow Vista Partners on Twitter @VistaPResearch to receive updates, thoughts, and ideas on Dow 30 Components, Select Emerging Growth Companies & Vista's Featured Companies.
SOURCE: Vista Partners LLC
